Drug Profile
RPR 110173
Latest Information Update: 03 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 16 Feb 1996 Preclinical development for Thrombosis in USA (Unknown route)